Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
16.30
+0.57 (3.62%)
Mar 4, 2026, 4:00 PM EST - Market closed
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 28.8, with a low estimate of 19 and a high estimate of 38. The average target predicts an increase of 76.69% from the current stock price of 16.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 8 |
| Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +102.45% | Feb 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +84.05% | Feb 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $27 | Strong Buy | Maintains | $26 → $27 | +65.64% | Jan 8, 2026 |
| Wedbush | Wedbush | Buy Maintains $25 → $34 | Buy | Maintains | $25 → $34 | +108.59% | Dec 9, 2025 |
| BTIG | BTIG | Strong Buy Maintains $32 → $38 | Strong Buy | Maintains | $32 → $38 | +133.13% | Nov 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
22.80M
EPS This Year
-3.60
from -3.11
EPS Next Year
-3.18
from -3.60
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 84.0M | ||||
| Avg | n/a | 22.8M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.28 | -2.25 | ||||
| Avg | -3.60 | -3.18 | ||||
| Low | -3.68 | -3.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.